A First-in-human, Open-label, Clinical Study to Assess the Safety, Tolerability, and Activity of OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Latest Information Update: 07 Jul 2025
At a glance
- Drugs OT C001 (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; First in man
- Acronyms C00101 study
- Sponsors EMERCell
Most Recent Events
- 26 May 2025 New trial record
- 22 Apr 2025 According to Onward Therapeutics media release, the company announced that its subsidiary, Emercell SAS, has received Investigational Medicinal Product Dossier (IMPD) approval from the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of OT-C001